(Q37203038)

18 August 2017

Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report (English)

1 reference

18 August 2017

1 reference

1 reference

Zhen-gang Yuan

1

1 reference

18 August 2017

Xiao-yi Dun

series ordinal

2

1 reference

18 August 2017

Yong-hua Li

series ordinal

3

1 reference

18 August 2017

Jian Hou

series ordinal

4

1 reference

18 August 2017

28 April 2009

1 reference

Journal of Hematology & Oncology

18 August 2017

1 reference

18 August 2017

2

1 reference

18 August 2017

19

1 reference

Proteasome inhibition in multiple myeloma

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Proteasome inhibition as a novel therapeutic target in human cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

A phase 2 study of bortezomib in relapsed, refractory myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Castleman's disease: A rare lymphoproliferative disorder.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Rituximab therapy for HIV-associated Castleman disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686727

Retinoic acid for treatment of multicentric Castleman's disease

4 December 2018

1 reference

12 December 2020

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody

1 reference

12 December 2020

The clinical behavior of localized and multicentric Castleman disease

1 reference

12 December 2020

Cervical Castleman's disease associated with benign M-proteinemia: report of a case

1 reference

12 December 2020

Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease

1 reference

12 December 2020

Multicentric Giant Lymph Node Hyperplasia

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-8722-2-19

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference

18 August 2017

PubMed publication ID

19400935

1 reference